KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Bristol Myers Squibb (BMY) over the last 13 years, with Q4 2025 value amounting to $3.8 billion.

  • Bristol Myers Squibb's Non-Current Deferred Tax Liability fell 1760.72% to $3.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.8 billion, marking a year-over-year decrease of 1760.72%. This contributed to the annual value of $3.8 billion for FY2025, which is 1760.72% down from last year.
  • Bristol Myers Squibb's Non-Current Deferred Tax Liability amounted to $3.8 billion in Q4 2025, which was down 1760.72% from $225.0 million recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Non-Current Deferred Tax Liability ranged from a high of $5.8 billion in Q4 2021 and a low of $225.0 million during Q3 2025
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $3.0 billion (2022), whereas its average is $2.7 billion.
  • In the last 5 years, Bristol Myers Squibb's Non-Current Deferred Tax Liability tumbled by 8615.06% in 2023 and then soared by 776.94% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Non-Current Deferred Tax Liability stood at $5.8 billion in 2021, then fell by 13.74% to $5.0 billion in 2022, then fell by 1.27% to $4.9 billion in 2023, then dropped by 6.77% to $4.6 billion in 2024, then fell by 17.61% to $3.8 billion in 2025.
  • Its last three reported values are $3.8 billion in Q4 2025, $225.0 million for Q3 2025, and $247.0 million during Q2 2025.